EN DE
Watch JHS Svendgaard Laboratories Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

JHS Svendgaard Laboratories Limited (JHS) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of JHS Svendgaard Laboratories Limited stock ₹4.38, price ₹8.05, that is 45.6% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive IN · ISIN INE544H01014

JS JHS Svendgaard Laboratories Limited logo Thin data Nov 16, 2026

JHS Svendgaard Laboratories Limited

JHS · NSE

Far too expensive (fair value 46% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +25% vs. a year ago. 
Quality 41/100 
Mixed vs. peers (5/11) 
Fair value ₹4.38 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y +0.3 %/yr in INR) 
Loss-making · -1.7% net margin (TTM) 
Negative free cash flow 
Narrow moat 16/100 · thin data
Thin data 
Watch JHS Svendgaard Laboratories Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹38.15 ₹6.55 Fair Value ₹4.38 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₹6.55 – ₹38.15 · fair‑value band ₹3.40 – ₹5.35 · the ₹8.05 price screens above the ₹4.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow JHS Svendgaard Laboratories in your weekly email

Every Wednesday you see whether JHS Svendgaard Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures, trades in, and sells a range of oral and dental products in India.

Show moreShow less

The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, whitening gels, talcum powders, sanitizers, detergents, and denture tablets. It also provides contract manufacturing services for oral care products. In addition, the company exports its products.

JHS Svendgaard Laboratories Limited was founded in 1997 and is based in New Delhi, India.

Stock analysis

JHS Svendgaard Laboratories Limited (JHS) currently trades at ₹8.05, while our model-based Fair Value estimate is ₹4.38, 46% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: ₹3.40 (bear) to ₹5.35 (bull), the price of ₹8.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

JHS Svendgaard Laboratories Limited reported revenue of ₹1.0B in FY2026 versus ₹855M in FY2022, a compound +4.4%/yr. Reported net income was −₹19.2M in FY2026.

Key figures

Market cap ₹703M (≈ $7.5M) Micro · P/S ratio 0.64 · EPS (TTM) ₹−0.2300 · Net margin −1.7% · Return on equity −1.1% · Return on assets (EBIT) −4.2% (5-year average) · Operating margin 1.1% · Revenue (TTM) ₹1.1B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −32% fair-value upside, at −46%, JHS screens richer than that median.

Fair Value models

Bear ₹3.40 Fair Value ₹4.38 Bull ₹5.35
Price ₹8.05 · Downside -45.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ₹3.40 ₹4.38 ₹5.35 67
NCAV (Graham) ₹1.73 ₹2.62 ₹3.27 55
All 2 models by family
Multiples
EV/EBITDA ₹3.40 ₹4.38 ₹5.35 67
Asset-Based
NCAV (Graham) ₹1.73 ₹2.62 ₹3.27 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 80
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 12/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+10.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2021 (pandemic). Over 10 years: +0.2% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.7% (2021) → −4.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

JHS screens overvalued: fair value 46% below the price. Compare with Colgate-Palmolive Company →

Compare JHS Svendgaard Laboratories Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 240 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −45.6% · Bottom 25%
Profitability
Return on assets −0.9% · Bottom 25%
Net margin (12 months) −1.7% · Bottom 25%
Operating margin (12 months) 1.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 24.6% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Household & Personal Products median · lower = cheaper

P/B 0.40× · Cheapest 25%
P/S (12 months) 0.63× · Cheaper than median
EV/EBITDA 10.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 19
PAST (return on equity)0 · sector 28
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)0 · sector 52

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Godrej Consumer Products Limited GODREJCP ₹870.75 ₹1,146 +32% vs JHS
Puig Brands, S.A PUIG €20.40 €24.28 +19% vs JHS
Henkel AG HEN €79.05 €83.75 +6% vs JHS
Beiersdorf Aktiengesellschaft, BEI €84.20 €69.09 −18% vs JHS
The Clorox Company CLX $109.46 $74.29 −32% vs JHS
Church & Dwight Co CHD $113.00 $65.04 −42% vs JHS
Colgate-Palmolive Company CL $99.67 $56.16 −44% vs JHS
Marico Limited MARICO ₹900.00 ₹493.84 −45% vs JHS
The Estée Lauder Companies Inc EL $111.75 $44.21 −60% vs JHS
Hindustan Unilever Limited HINDUNILVR ₹1,993 ₹775.25 −61% vs JHS

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

JHS Svendgaard Laboratories Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "JHS Svendgaard Laboratories Limited Fair Value". https://www.fairvalue-calculator.com/stock/JHS

Frequently asked questions

Is JHS Svendgaard Laboratories Limited (JHS) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of ₹4.38 versus a price of ₹8.05, about 46% lower (overvalued).
What is the fair value of JHS?
Our model-based fair value for JHS Svendgaard Laboratories Limited is ₹4.38 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹8.05.
What is the quality score of JHS?
JHS Svendgaard Laboratories Limited has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JHS Svendgaard Laboratories Limited (JHS)?
Our model-based price target is the fair value of ₹4.38 (as of Nov 16, 2026) from 2 valuation models. Cautious scenario ₹3.40, optimistic scenario ₹5.35. It is a calculation from audited fundamentals, not an analyst target.
What is the JHS Svendgaard Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹4.38, about 46% lower versus a price of ₹8.05 (overvalued). Cautious scenario ₹3.40, optimistic scenario ₹5.35. The calculation is refreshed regularly with new filings.
What is the revenue of JHS Svendgaard Laboratories Limited (JHS)?
JHS Svendgaard Laboratories Limited reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of JHS Svendgaard Laboratories Limited (JHS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JHS Svendgaard Laboratories Limited it is ₹4.38 per share (as of Nov 16, 2026), against a price of ₹8.05. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is JHS Svendgaard Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, JHS trades above its calculated fair value: price ₹8.05, fair value ₹4.38, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JHS?
No. The price is what the market pays today (₹8.05); the fair value is what the company's own numbers justify (₹4.38). For JHS Svendgaard Laboratories Limited the two are ₹3.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is JHS Svendgaard Laboratories Limited worth?
The market values JHS Svendgaard Laboratories Limited at about ₹703M (market capitalisation, as of Nov 16, 2026). Per share that is ₹8.05; our models calculate a fair value of ₹4.38 per share.
What do the bullish and bearish scenarios say about JHS?
Our models span a range for JHS Svendgaard Laboratories Limited: cautious scenario ₹3.40, base ₹4.38, optimistic ₹5.35 per share (as of Nov 16, 2026, price ₹8.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JHS Svendgaard Laboratories Limited (JHS)?
Balance-sheet figures for JHS Svendgaard Laboratories Limited (as of Nov 16, 2026): return on equity −1.1%, debt of 0.03 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is JHS from its 52-week high?
JHS Svendgaard Laboratories Limited trades at ₹8.05, about 35% below its 52-week high of ₹12.45 and 23% above the low of ₹6.55 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4.38 is for.
Which stocks are comparable to JHS Svendgaard Laboratories Limited?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JHS Svendgaard Laboratories Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹8.05, calculated fair value ₹4.38 (−46%), Quality Score 41/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JHS calculated?
We run JHS Svendgaard Laboratories Limited through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ₹4.38 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. JHS Svendgaard Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JHS Svendgaard Laboratories Limited (JHS)?
The closing price on Nov 13, 2026 was ₹8.05. Our model-based fair value is ₹4.38, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JHS Svendgaard Laboratories Limited right now?
The price sits above even our optimistic bull case (₹5.35). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of JHS Svendgaard Laboratories Limited

How large is the market capitalisation of JHS Svendgaard Laboratories Limited (JHS)?
The market capitalisation of JHS Svendgaard Laboratories Limited is ₹703M (≈ $7.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JHS Svendgaard Laboratories Limited (JHS)?
The price-to-sales ratio of JHS Svendgaard Laboratories Limited is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JHS Svendgaard Laboratories Limited (JHS)?
Earnings per share at JHS Svendgaard Laboratories Limited are ₹−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JHS Svendgaard Laboratories Limited (JHS)?
The net margin of JHS Svendgaard Laboratories Limited is −1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JHS Svendgaard Laboratories Limited (JHS)?
The return on equity (ROE) of JHS Svendgaard Laboratories Limited is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JHS Svendgaard Laboratories Limited (JHS)?
On an EBIT basis the return on assets of JHS Svendgaard Laboratories Limited is −4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JHS Svendgaard Laboratories Limited (JHS)?
The operating margin of JHS Svendgaard Laboratories Limited is 1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JHS Svendgaard Laboratories Limited (JHS)?
Revenue at JHS Svendgaard Laboratories Limited is growing 24.6% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does JHS Svendgaard Laboratories Limited (JHS) generate?
The free cash flow of JHS Svendgaard Laboratories Limited is −₹149M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does JHS Svendgaard Laboratories Limited (JHS) hold?
JHS Svendgaard Laboratories Limited holds more cash than debt, ₹42.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch JHS Svendgaard Laboratories Limited in the live analysis

One click puts JHS Svendgaard Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.